Buscar
Mostrando ítems 31-40 de 122
Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine
(2021)
BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible of the current pandemic ongoing all around the world. Since its discovery in 2019, several circulating variants have emerged ...
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil
(The Lancet Infectious Diseases, 2022)
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
(Nature Research, 2022)
Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile
(2021)
Background. The development of effective vaccines against coronavirus disease 2019 is a global priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine with promising safety ...
Orientalismo en el discurso de prensa de Brasil y Chile sobre la vacuna CoronaVac
(Universidad de Chile, 2022)
Introducción: La pandemia de COVID-19 incrementó el orientalismo, que es el estilo de pensamiento basado en la dicotomía Oriente y Occidente. Simultáneamente, la ansiedad y el miedo en la población generó un exceso en el ...
Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naive and previously infected individuals
(2022)
Interpretation The decay of nAbs titres in previously infected individuals over time indicates that vaccination is needed to boost humoral memory responses. Immunization of naydve individuals with two doses of CoronaVac ...
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study
(Elsevier Ltd, 2022)
© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseBackground: Several countries have authorised or begun using a booster vaccine dose against COVID-19. Policy makers ...